209 related articles for article (PubMed ID: 25817387)
1. Structure of Prolyl-tRNA Synthetase-Halofuginone Complex Provides Basis for Development of Drugs against Malaria and Toxoplasmosis.
Jain V; Yogavel M; Oshima Y; Kikuchi H; Touquet B; Hakimi MA; Sharma A
Structure; 2015 May; 23(5):819-829. PubMed ID: 25817387
[TBL] [Abstract][Full Text] [Related]
2. The cytoplasmic prolyl-tRNA synthetase of the malaria parasite is a dual-stage target of febrifugine and its analogs.
Herman JD; Pepper LR; Cortese JF; Estiu G; Galinsky K; Zuzarte-Luis V; Derbyshire ER; Ribacke U; Lukens AK; Santos SA; Patel V; Clish CB; Sullivan WJ; Zhou H; Bopp SE; Schimmel P; Lindquist S; Clardy J; Mota MM; Keller TL; Whitman M; Wiest O; Wirth DF; Mazitschek R
Sci Transl Med; 2015 May; 7(288):288ra77. PubMed ID: 25995223
[TBL] [Abstract][Full Text] [Related]
3. Conformational heterogeneity in apo and drug-bound structures of Toxoplasma gondii prolyl-tRNA synthetase.
Mishra S; Malhotra N; Kumari S; Sato M; Kikuchi H; Yogavel M; Sharma A
Acta Crystallogr F Struct Biol Commun; 2019 Nov; 75(Pt 11):714-724. PubMed ID: 31702585
[TBL] [Abstract][Full Text] [Related]
4. Structural and functional analysis of the anti-malarial drug target prolyl-tRNA synthetase.
Jain V; Kikuchi H; Oshima Y; Sharma A; Yogavel M
J Struct Funct Genomics; 2014 Dec; 15(4):181-90. PubMed ID: 25047712
[TBL] [Abstract][Full Text] [Related]
5. ATP-directed capture of bioactive herbal-based medicine on human tRNA synthetase.
Zhou H; Sun L; Yang XL; Schimmel P
Nature; 2013 Feb; 494(7435):121-4. PubMed ID: 23263184
[TBL] [Abstract][Full Text] [Related]
6. Targeting Prolyl-tRNA Synthetase to Accelerate Drug Discovery against Malaria, Leishmaniasis, Toxoplasmosis, Cryptosporidiosis, and Coccidiosis.
Jain V; Yogavel M; Kikuchi H; Oshima Y; Hariguchi N; Matsumoto M; Goel P; Touquet B; Jumani RS; Tacchini-Cottier F; Harlos K; Huston CD; Hakimi MA; Sharma A
Structure; 2017 Oct; 25(10):1495-1505.e6. PubMed ID: 28867614
[TBL] [Abstract][Full Text] [Related]
7. Conformational changes in human prolyl-tRNA synthetase upon binding of the substrates proline and ATP and the inhibitor halofuginone.
Son J; Lee EH; Park M; Kim JH; Kim J; Kim S; Jeon YH; Hwang KY
Acta Crystallogr D Biol Crystallogr; 2013 Oct; 69(Pt 10):2136-45. PubMed ID: 24100331
[TBL] [Abstract][Full Text] [Related]
8. Structural analyses of the malaria parasite aminoacyl-tRNA synthetases provide new avenues for antimalarial drug discovery.
Chhibber-Goel J; Yogavel M; Sharma A
Protein Sci; 2021 Sep; 30(9):1793-1803. PubMed ID: 34184352
[TBL] [Abstract][Full Text] [Related]
9. Exploring dual inhibitory role of febrifugine analogues against Plasmodium utilizing structure-based virtual screening and molecular dynamic simulation.
Pandey RK; Narula A; Naskar M; Srivastava S; Verma P; Malik R; Shah P; Prajapati VK
J Biomol Struct Dyn; 2017 Mar; 35(4):791-804. PubMed ID: 26984239
[TBL] [Abstract][Full Text] [Related]
10. Halofuginone and other febrifugine derivatives inhibit prolyl-tRNA synthetase.
Keller TL; Zocco D; Sundrud MS; Hendrick M; Edenius M; Yum J; Kim YJ; Lee HK; Cortese JF; Wirth DF; Dignam JD; Rao A; Yeo CY; Mazitschek R; Whitman M
Nat Chem Biol; 2012 Feb; 8(3):311-7. PubMed ID: 22327401
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance.
Tye MA; Payne NC; Johansson C; Singh K; Santos SA; Fagbami L; Pant A; Sylvester K; Luth MR; Marques S; Whitman M; Mota MM; Winzeler EA; Lukens AK; Derbyshire ER; Oppermann U; Wirth DF; Mazitschek R
Nat Commun; 2022 Aug; 13(1):4976. PubMed ID: 36008486
[TBL] [Abstract][Full Text] [Related]
12. Chemical synthesis of febrifugine and analogues.
Smullen S; McLaughlin NP; Evans P
Bioorg Med Chem; 2018 May; 26(9):2199-2220. PubMed ID: 29681487
[TBL] [Abstract][Full Text] [Related]
13. The Adaptive Proline Response in P. falciparum Is Independent of PfeIK1 and eIF2α Signaling.
Fagbami L; Deik AA; Singh K; Santos SA; Herman JD; Bopp SE; Lukens AK; Clish CB; Wirth DF; Mazitschek R
ACS Infect Dis; 2019 Apr; 5(4):515-520. PubMed ID: 30773881
[TBL] [Abstract][Full Text] [Related]
14. The chemistry and biology of febrifugine and halofuginone.
McLaughlin NP; Evans P; Pines M
Bioorg Med Chem; 2014 Apr; 22(7):1993-2004. PubMed ID: 24650700
[TBL] [Abstract][Full Text] [Related]
15. Identification of Selective Novel Hits against
Nyamai DW; Tastan Bishop Ö
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471245
[TBL] [Abstract][Full Text] [Related]
16. Double drugging of prolyl-tRNA synthetase provides a new paradigm for anti-infective drug development.
Manickam Y; Malhotra N; Mishra S; Babbar P; Dusane A; Laleu B; Bellini V; Hakimi MA; Bougdour A; Sharma A
PLoS Pathog; 2022 Mar; 18(3):e1010363. PubMed ID: 35333915
[TBL] [Abstract][Full Text] [Related]
17. Selective inhibition of an apicoplastic aminoacyl-tRNA synthetase from Plasmodium falciparum.
Hoen R; Novoa EM; López A; Camacho N; Cubells L; Vieira P; Santos M; Marin-Garcia P; Bautista JM; Cortés A; Ribas de Pouplana L; Royo M
Chembiochem; 2013 Mar; 14(4):499-509. PubMed ID: 23444099
[TBL] [Abstract][Full Text] [Related]
18. The growing pipeline of natural aminoacyl-tRNA synthetase inhibitors for malaria treatment.
Saint-Léger A; Sinadinos C; Ribas de Pouplana L
Bioengineered; 2016 Apr; 7(2):60-4. PubMed ID: 26963157
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with l-proline.
Adachi R; Okada K; Skene R; Ogawa K; Miwa M; Tsuchinaga K; Ohkubo S; Henta T; Kawamoto T
Biochem Biophys Res Commun; 2017 Jun; 488(2):393-399. PubMed ID: 28501621
[TBL] [Abstract][Full Text] [Related]
20. Recombinant expression, purification, and crystallization of the glutaminyl-tRNA synthetase from Toxoplasma gondii.
van Rooyen JM; Hakimi MA; Belrhali H
Protein Expr Purif; 2015 Jun; 110():115-21. PubMed ID: 25736594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
